Muscular Atrophy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Muscular Atrophy. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Muscular Atrophy receives a directional strategic score of 60/100, combining unmet need (65/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (95/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.

The reproducible entity is Patsnap disease ID b69d6b0df0164f86b1262fafcf3768de with MeSH identifier D009133. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Multiple system atrophy pathology is associated with primary Sjögren’s syndrome

In addition to our pSS cohort, we examined 4 separate independent studies describing the incidence or prevalence of MSA in the general population. A study by Bower et al. in Olmsted county, Minnesota, USA, and by Bjornsdottir et al. in Iceland, reported incidence data (9, 10). The other two studies, by Schrag et al. in London, United Kingdom, and by Chrysostome et al. in France, recorded prevalence data (8, 11). For the 2 studies with prevalence data, we calculated estimated incidence rates using an 8.5 year median survival. The lifetime annual incidence of MSA in our pSS cohort was significantly higher than the incidence of MSA in all 4 of these studies. The ratios of incidence in our pSS cohort compared with the populations studied were as follows: for Bower et al. (9), 27 (95% CI = 7.2–98.5); for Bjornsdottir et al. (10), 26 (95% CI = 7.7–88.5), for Schrag et al. (8), 32 (95% CI = 7.3–146), and for Chrysostome et al. (11), 77 (95% CI = 23–256) (Table 2 and Figure 2). Patients with pSS have a higher prevalence of MSA compared with patients with other autoimmune diseases To evaluate whether MSA was associated with pSS compared with patients with other autoimmune diseas- es, we assembled a control cohort of 776 patients. Their mean age was 57.6 years, 607 patients (78%) were Table 1. Clinicopathologic characteristics of patients with MSA and pSS

Review the epidemiology source

Epidemiology evidence 2: Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany

Myasthenia gravis (MG) is a rare, chronic autoimmune disease with symptoms of fluctuating muscular weakness and fatigability. The aim of this retrospective cohort study was to estimate the prevalence and incidence of MG in Germany, and to understand the burden of disease and treatment patterns, based on anonymized German claims data. Two patient samples were identified: (1) incident MG patients with newly onset disease between 2015 and 2019, and (2) prevalent MG patients in 2019. In total, 775 incident MG patients with a mean age of 66.9 years; and 1,247 prevalent MG patients with a mean age of 68.6 years were included. The prevalence for Germany was estimated to be 39.3/10 0,0 0 0 on 31/12/2019; the incidence in 2019 was 4.6 cases/10 0,0 0 0 persons. The 12-month mortality was 5.7. For 31.5% of the incident patients, no MG treatment was observed in the first year after the index date. Of all incident patients, 29.9% experienced an exacerbation, and 6.7% a myasthenic crisis during the observation. Our study indicates that a substantial proportion of MG patients remains untreated. Many MG patients still experience exacerbations / MG crises. MG seems to be associated with an excess mortality in comparison to the general non-MG population. Article history: y Received 7 July 2022 J y Revised 20 January 2023 J y Accepted 9 February 2023 Keywords: Myasthenia gravis Prevalence Incidence Treatment Burden of disease 1. Introduction Myasthenia Gravis (MG) is a rare, chronic autoimmune disease characterized by dysfunction and damage at the neuromuscular junction, driven by pathogenic IgG

Review the epidemiology source

Epidemiology evidence 3: Epidemiology of Neuralgic Amyotrophy—A RetrospectiveAnalysis of Data From a Large German HealthInsurance Company Epidemiology of Neuralgic Amyotrophy—A Retrospective Analysis of Data From a Large German Health Insurance Company

Epidemiology of Neuralgic Amyotrophy—A RetrospectiveAnalysis of Data From a Large German HealthInsurance Company OPEN ACCESS Epidemiology of Neuralgic Amyotrophy—A Retrospective Analysis of Data From a Large German Health Insurance Company Johannes Fabian Holle1,2 | Andreas Leha3 | Carolin Polte4 | Volker Limmroth1 | Wolfram Windisch2,5 | Maximilian Zimmermann2,5 1Department of Neurology, Cologne-­Merheim, Hospitals of the City of Cologne, Cologne, Germany | 2Health Faculty/Department for Human Medicine, University of Witten/Herdecke, Witten, Germany | 3Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany | 4AOK Federal Association, Outpatient Analysis and Care Scientific Institute of the AOK, Berlin, Germany | 5Cologne-­Merheim Lung Clinic, Hospitals of the City of Cologne, Cologne, Germany Correspondence: Johannes Fabian Holle (johannes.holle@uni-wh.de) Received: 5 April 2025 | Revised: 1 October 2025 | Accepted: 5 November 2025 Funding: The authors received no specific funding for this work. Keywords: epidemiology | incidence | neuralgic amyotrophy | phrenic neuropathy | prevalence ABSTRACT Introduction/Aims: Neuralgic amyotrophy (NA, Parsonage–Turner syndrome) is a common, multifocal, autoimmune in- flammatory disease that predominantly affects proximal nerve segments of the shoulder girdle. Despite the high incidence of 100/100,000, epidemiologic data based on larger cohorts are still lacking. This study aims to address this issue. Methods: A retrospective evaluation of billing data from an average of approximately 26,000,000 insure

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Muscular Atrophy, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Muscular Atrophy thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: RPE65

Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore (PubMed:16116091). Essential for the production of 11-cis retinal for both rod and cone photoreceptors (PubMed:17848510). Also capable of catalyzing the isomerization of lutein to meso-zeaxanthin an eye-specific carotenoid (PubMed:28874556). The soluble form binds vitamin A (all-trans-retinol), making it available for LRAT processing to all-trans-retinyl ester. The membrane form, palmitoylated by LRAT, binds all-trans-retinyl esters, making them available for IMH (isomerohydrolase) processing to all-cis-retinol. The soluble form is regenerated by transferring its palmitoyl groups onto 11-cis-retinol, a reaction catalyzed by LRAT (By similarity).

The mechanism anchor is RPE65. It is a pathway hypothesis, not a claim that every Muscular Atrophy patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 3396 registered studies. Recent sampled records include:

• JPRN-jRCT2033260412 — Specified use-results survey of Zolgensma Intrathecal Injection (spinal muscular atrophy); 募集中; Not Applicable; sponsor Novartis Pharma KK; enrollment 80.
• NCT07772908 — Efficacy of Protein Supplementation in Preventing Muscle Mass Loss During the Weight Loss Process. (GPOWER); Active, not recruiting; Not Applicable; sponsor Althaia SA Indústria Farmacêutica; enrollment 76.
• ChiCTR2600130256 — Neuromodulatory Effects of Transcranial Electrical Stimulation in Older Adults With Sarcopenia; Not yet recruiting; Not Applicable; sponsor First Affiliated Hospital Of Fujian Medical University; enrollment 57.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 8 recent directly matched transaction records:

• Curi Bio and Cook MyoSite Announce Strategic Scientific Collaboration to Advance Translational Human Muscle Disease Models (2025-04-30). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• Allosteric Bioscience, Inc. Licenses Sarcopenia (Muscle Loss) Prevention/Treatment Technology from Johns Hopkins University (2025-03-10). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• ENCell and Lucy Biotech Sign a Strategic Alliance and Licensing Agreement for the Next generation Mesenchymal Stem Cell Therapy (EN001) (2024-09-09). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate RPE65 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Muscular Atrophy merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if RPE65 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Muscular Atrophy is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.